Table 1.

Clinical trials evaluating entospletinib as monotherapy or in combination therapy.

Entospletinib: monotherapy or combination therapy	Condition	Title	Reference/ClinicalTrials.gov identifier
Monotherapy	Relapsed or refractory CLL	An open-label phase II trial of entospletinib (GS-9973), a selective SYK inhibitor, in CLL	Sharman et al. [2015a]
			NCT01799889
Monotherapy	CLL refractory to prior therapy with ibrutinib or idelalisib	Clinical activity of entospletinib (GS-9973), a selective SYK inhibitor, in patients with CLL previously treated with an inhibitor of BCR pathway signaling	Sharman et al. [2015d]
			NCT01799889
Monotherapy	Relapsed or refractory iNHL (FL, LPL/WM, SLL, MZL)	Phase II trial of entospletinib (GS-9973), a selective SYK inhibitor, in CLL and SLL	Sharman et al. [2015b]
			NCT01799889
		Phase II trial of entospletinib (GS-9973), a selective SYK inhibitor, in iNHL	Sharman et al. [2015c]
Combination therapy with idelalisib	Relapsed or refractory CLL	Phase II study of idelalisib and entospletinib; pneumonitis limits combination therapy in relapsed refractory CLL and NHL	Study halted due to excessive immune-related toxicities Barr et al. [2015]
			NCT01796470
Combination therapy with vincristine and dexamethasone	Relapsed or refractory ALL	Safety and efficacy of entospletinib with vincristine and dexamethasone in adults with relapsed or refractory ALL	Minden et al. [2015] NCT02404220
Combination with vincristine and vincristine-based combination chemotherapy	Relapsed or refractory NHL	Safety and efficacy of entospletinib (GS-9973) combined with VCR and VCR-based combination chemotherapy in adult participants with NHL	NCT02568683

ALL, acute lymphoid leukemia; BCR, B-cell receptor; CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; LPL, lymphoplasmacytic lymphoma; MZL, marginal zone lymphoma; iNHL, indolent non-Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma; SLL, small lymphocytic lymphoma; SYK, spleen tyrosine kinase; VCR, vincristine; WM, Waldenström’s macroglobulinemia.